| Literature DB >> 23538558 |
Dipannita Dutta1, Julie G Donaldson.
Abstract
We discuss here the variety of approaches that have been taken to inhibit different forms of endocytosis. Typically, both non-specific and specific chemical inhibitors of endocytosis are tried in order to "classify" entry of a new plasma membrane protein into one of the various types of endocytosis. This classification can be confirmed through genetic approaches of protein depletion or overexpression of mutants of known endocytosis machinery components. Although some new compounds have been designed to be selective in biochemical assays, we caution investigators to be alert to the unintended consequences that sometimes arise when these compounds are applied to intact cells.Entities:
Keywords: chemical inhibitor; clathrin-independent endocytosis; clathrin-mediated endocytosis; endocytosis; inhibitor; phagocytosis; pinocytosis
Year: 2012 PMID: 23538558 PMCID: PMC3607622 DOI: 10.4161/cl.23967
Source DB: PubMed Journal: Cell Logist ISSN: 2159-2780

Figure 1. Different types of endocytosis. Endocytosis can be broadly classified into pinocytosis and phagocytosis. Phagocytosis involves the internalization of large particles like bacteria whereas macropinocytosis involves the internalization of enlarged fluid-filled endosomes; both processes are driven by actin (shown as hatched lines). Clathrin-mediated endocytosis (CME) is a selective mechanism whereby cell surface proteins containing specific sorting sequences are gathered into membrane depressions by associating with adaptor proteins which recruit clathrin (*). CME endosomes pinch off from the cell surface by recruiting the dynamin GTPase (•) to the bud neck. Clathrin-independent endocytosis (CIE) is shown here as one form, although there are reports of distinct variations of CIE. Most CIE is clathrin- and dynamin-independent and cholesterol-dependent and includes both the CLIC/GEEC and Arf6-associated forms of CIE. In addition other CIE modes (caveolae- and RhoA-dependent) are dynamin-dependent.
Table 1. Chemical and genetic endocytosis inhibitors
| Endocytosis inhibitors | Pathways targeted | Mode of action | Comments |
|---|---|---|---|
| Hypertonic sucrose | CME | Traps clathrin in microcages | Nonspecific; interferes with fluid phase macropinocytosis |
| Potassium depletion | CME | Aggregates clathrin | Nonspecific; affects actin cytoskeleton |
| Cytosol acidification | CME | Inhibits the scission of the clathrin pits from the membrane | Interferes with macropinocytosis and actin cytoskeleton |
| Chlorpromazine | CME | Translocates clathrin and AP2 from the cell surface to intracellular endosomes | Inhibits CIE in some cells |
| Monodansylcadaverine | CME | Stabilizes CCVs | Global changes in actin dynamics |
| Phenylarsine oxide | CME | Not clearly known. | Inhibits macropinocytosis |
| Chloroquine | CME | Affects the function of CCVs | |
| Monensin | CME | Affects the proton gradient | |
| Phenothiazines | CME; phagocytosis | Affects the formation of CCVs | |
| Methyl-β-cyclodextrin | Lipid raft | Removes cholesterol out of the plasma membrane | Interferes fluid phase endocytosis |
| Filipin | CIE | Binds to cholesterol in the membrane | Toxic at higher concentration; inhibits CME |
| Cytochalasin D, latrunculin | Phagocytosis; macropinocytosis | Depolymerizes F-actin | Affects most endocytic pathways |
| Amiloride | Macropinocytosis | Inhibits Na+/H+ exchange | May affect actin |
| Dynasore | CME | Blocks GTPase activity of Dynamin | Interferes with actin |
| Dynoles, dyngoes | CME | Blocks GTPase activity of Dynamin I | Interferes with actin |
| Pitstop 2 | CME | Interferes with binding of proteins to the N-terminal domain of clathrin | Most forms of CIE affected; causes decrease in PM mobility |
| Dynamin mutant, Dyn K44A | CME | Defective in GTP hydrolysis | Enhances fluid phase uptake |
| AP180C | CME | Sequesters clathrin | Other secondary effects (e.g., changes in gene expression) might occur due to overexpression and knocking down for several days |
| Eps15 mutant | CME | Inhibits clathrin pits assembly | |
| Clathrin Hub mutant | CME | Dominant negative mutant of clathrin | |
| siRNA of clathrin | CME | Blocks formation of clathrin pits | |
| siRNA of AP2 | CME | Blocks formation of AP2-dependent clathrin pits | |
CME, clathrin-mediated endocytosis; CIE, clathrin-independent endocytosis.